2 weeks Ago By ABMN Staff
Federated Hermes Inc. trimmed its stake in Nurix Therapeutics, Inc. ( NASDAQ:NRIX – Free Report ) by 46.
4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,640 shares of the company’s stock after selling 19,564 shares during the quarter. Federated Hermes Inc.
’s holdings in Nurix Therapeutics were worth $427,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. JPMorgan Chase & Co.
increased its position in Nurix Therapeutics by 85.2% in the 3rd quarter. JPMorgan Chase & Co.
now owns 68,148 shares of the company’s stock valued at $1,531,000 after buying an additional 31,352 shares in the last quarter. Barclays PLC grew its stake in shares of Nurix Therapeutics by 77.9% in the 3rd quarter.
Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after acquiring an additional 56,190 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Nurix Therapeutics by 42.
7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock valued at $14,869,000 after purchasing an additional 235,971 shares during the last quarter.
Norges Bank bought a new position in shares of Nurix Therapeutics during the fourth quarter valued at about $6,006,000. Finally, Raymond James Financial Inc. bought a new stake in Nurix Therapeutics in the 4th quarter worth about $1,026,000.
Wall Street Analysts Forecast Growth A number of research analysts have issued reports on the company. Needham & Company LLC reduced their price objective on Nurix Therapeutics from $28.00 to $27.
00 and set a “buy” rating for the company in a research note on Wednesday, April 9th. Wells Fargo & Company dropped their target price on shares of Nurix Therapeutics from $32.00 to $25.
00 and set an “overweight” rating on the stock in a research note on Wednesday, April 9th. Stifel Nicolaus dropped their price objective on Nurix Therapeutics from $36.00 to $35.
00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. JPMorgan Chase & Co. lowered their target price on Nurix Therapeutics from $31.
00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Finally, Stephens reissued an “overweight” rating and issued a $31.
00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.
44. Nurix Therapeutics Stock Up 4.5 % Nurix Therapeutics stock opened at $10.
24 on Friday. The firm has a fifty day simple moving average of $13.32 and a two-hundred day simple moving average of $18.
85. Nurix Therapeutics, Inc. has a twelve month low of $8.
18 and a twelve month high of $29.56. The company has a market capitalization of $780.
66 million, a PE ratio of -3.54 and a beta of 2.23.
Nurix Therapeutics ( NASDAQ:NRIX – Get Free Report ) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.
72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.
65% and a negative net margin of 354.85%. The business had revenue of $18.
45 million for the quarter, compared to analysts’ expectations of $12.78 million. During the same period in the previous year, the firm earned ($0.
76) EPS. As a group, equities analysts expect that Nurix Therapeutics, Inc. will post -2.
99 earnings per share for the current fiscal year. Insiders Place Their Bets In related news, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.
49, for a total value of $84,404.25. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $488,660.
76. This trade represents a 14.73 % decrease in their ownership of the stock.
The sale was disclosed in a legal filing with the SEC, which is available through this link . Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.
85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.
45. This trade represents a 6.19 % decrease in their position.
The disclosure for this sale can be found here . Insiders have sold a total of 12,326 shares of company stock valued at $213,449 in the last quarter. Insiders own 7.
20% of the company’s stock. Nurix Therapeutics Profile ( Free Report ) Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Recommended Stories Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
